Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average) (2022 - 2026)

Compass Therapeutics' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $186.4 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 34.84% to $186.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $186.4 million, a 34.84% increase, with the full-year FY2025 number at $157.7 million, up 14.78% from a year prior.
  • Shares Outstanding (Weighted Average) hit $186.4 million in Q1 2026 for Compass Therapeutics, up from $157.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CMPX hit a ceiling of $186.4 million in Q1 2026 and a floor of $105.2 million in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $139.3 million across 5 years, with a median of $137.2 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): grew 0.85% in 2025 and later surged 34.84% in 2026.
  • Tracing CMPX's Shares Outstanding (Weighted Average) over 5 years: stood at $105.2 million in 2022, then grew by 20.76% to $127.0 million in 2023, then increased by 8.15% to $137.4 million in 2024, then grew by 14.78% to $157.7 million in 2025, then increased by 18.2% to $186.4 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CMPX at $186.4 million in Q1 2026, $157.7 million in Q4 2025, and $168.8 million in Q3 2025.